<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01665677</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00021090</org_study_id>
    <secondary_id>WVU 011012</secondary_id>
    <nct_id>NCT01665677</nct_id>
  </id_info>
  <brief_title>Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation</brief_title>
  <official_title>Phase II Study of Atorvastatin, Micro-dose Methotrexate and Tacrolimus Administered Only to Transplant Recipients for the Prophylaxis of Acute Graft-versus-host Disease Following Allogeneic Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mehdi Hamadani</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>West Virginia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hematopoietic stem cell transplantation is a procedure in which a person receives blood&#xD;
      forming stem cells from a person called a &quot;donor.&quot; The stem cells can be obtained from the&#xD;
      hollow part of the hip bone or from blood.&#xD;
&#xD;
      A serious problem with this treatment is graft-versus-host disease (GVHD). This happens when&#xD;
      stem cells from the donor attack normal cells of the recipient. Currently, there is no&#xD;
      universal standard of care in the United States to prevent GVHD.&#xD;
&#xD;
      This study is being done to see if a medicine that is used to lower cholesterol can also help&#xD;
      in reducing GVHD.&#xD;
&#xD;
      Patients will receive atorvastatin daily by mouth starting 14 days before stem cell&#xD;
      transplant. They will continue to take atorvastatin until 180 days after transplant. This&#xD;
      medicine may be stopped earlier if there is a bad side effect or a severe GVHD. Patients will&#xD;
      also receive standard treatment to prevent GVHD. Patients will undergo many tests that are&#xD;
      standard for their treatment at West Virginia University (WVU), including blood tests to&#xD;
      check blood counts, kidney function and HIV status; blood test to check for pregnancy; Multi&#xD;
      Gated Acquisition Scan (MUGA scan)or echocardiogram to test heart function; lung function&#xD;
      testing; and bone marrow aspirate or biopsy. Patients will also have the option to provide&#xD;
      blood samples for optional research related to the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute graft-versus-host disease (GVHD) is one of the most frequent complications after&#xD;
      allogeneic hematopoietic stem cell transplantation (HSCT).(1) It develops in 30-75% of&#xD;
      recipients of allogeneic HSCT depending on the degree of histocompatibility between the donor&#xD;
      and the recipient, number of T-cells in the graft, recipient's age and GVHD prophylactic&#xD;
      regimen used. (2-4) Novel strategies designed to effectively prevent the development of this&#xD;
      life threatening complication of allogeneic transplantation are urgently needed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 20, 2014</start_date>
  <completion_date type="Actual">July 9, 2021</completion_date>
  <primary_completion_date type="Actual">July 9, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Matched sibling transplants who develop grade II-IV acute GVHD.</measure>
    <time_frame>Up until Year 5</time_frame>
    <description>The number of subjects who develop grades II-IV acute GVHD will be assessed by consensus criteria and graded on Bone Marrow Transplant Clinical Trials Network Manual of Procedures suggested grading sheets.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Matched unrelated donors transplants who develop grade II-IV acute GVHD.</measure>
    <time_frame>Up until Year 5</time_frame>
    <description>The number of subjects who develop grade II-IV acute GVHD. Acute GVHD will be assessed by consensus criteria and graded on Bone Marrow Transplant Clinical Trials Network Manual of Procedures suggested grading sheets.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Matched sibling transplants who develop grade II-IV chronic GVHD.</measure>
    <time_frame>Up until Year 5</time_frame>
    <description>The number of subjects who develop grade II-IV chronic GVHD. Chronic GVHD diagnosis and grading will be according to National Institutes of Health (NIH) Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matched unrelated donors transplants who develop grade II-IV chronic GVHD.</measure>
    <time_frame>Up until Year 5</time_frame>
    <description>The number of subjects who develop grade II-IV chronic GVHD. Chronic GVHD diagnosis and grading will be according to NIH Criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Graft vs Host Disease</condition>
  <arm_group>
    <arm_group_label>Atorvastatin calcium (Lipitor)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin will be administered at a dose of 40 mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning.&#xD;
Patients will receive atorvastatin until +180 days or until the patient develops grade II-IV acute GVHD, extensive chronic GVHD, or any grade 3-4 toxicity related to atorvastatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unrelated Donor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin will be administered at a dose of 40 mg orally daily starting on day -14, to permit an approximately 1-week observation period to rule out any acute atorvastatin-induced side effects before the initiation of transplant conditioning.&#xD;
Patients will receive atorvastatin until +180 days or until the patient develops grade II-IV acute GVHD, extensive chronic GVHD, or any grade 3-4 toxicity related to atorvastatin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin calcium</intervention_name>
    <description>40 mg PO daily</description>
    <arm_group_label>Atorvastatin calcium (Lipitor)</arm_group_label>
    <arm_group_label>Unrelated Donor</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of a hematological malignancy or bone marrow failure syndrome&#xD;
             suitable for allogeneic stem cell transplantation in the opinion of treating&#xD;
             transplant physician.&#xD;
&#xD;
          -  Patients aged 18-75 years of age are eligible. Patients with age &gt; 18 and ≤ 50 years&#xD;
             will be eligible for myeloablative conditioning (MAC), while patients &gt; 50 years of&#xD;
             age, or those with previous history of autologous transplantation, high hematopoietic&#xD;
             cell transplant comorbidity index (HCT-CI) score (&gt;2), and baseline diagnosis of&#xD;
             hodgkin's lymphoma, chronic lymphocytic leukemia and follicular lymphoma will be&#xD;
             suitable for reduced intensity conditioning (RIC) transplantation (however intensity&#xD;
             of conditioning regimen will remain at the discretion of treating physician).&#xD;
&#xD;
          -  All patients must have at least one suitable human leukocyte antigen (HLA)-matched&#xD;
             sibling or unrelated donor according to transplant center's guidelines (for selection&#xD;
             of appropriate sibling donor).&#xD;
&#xD;
          -  Patient must provide informed consent.&#xD;
&#xD;
          -  Left ventricular ejection fraction ≥ 40%.&#xD;
&#xD;
          -  Bilirubin ≤ 2 x the upper limit of normal (ULN) and aspartate aminotransferase (AST),&#xD;
             and alanine aminotransferase (ALT) ≤ 3 x ULN; and absence of hepatic cirrhosis. For&#xD;
             patients with Gilbert's syndrome, bilirubin ≤ 3 x ULN is permitted.&#xD;
&#xD;
          -  Adequate renal function as defined by a serum creatinine clearance of ≥ 40% of normal&#xD;
             calculated by Cockcroft-Gault equation.&#xD;
&#xD;
          -  Carbon monoxide diffusing capacity (DLCOcor) corrected for hemoglobin or forced&#xD;
             expiratory volume at one second (FEV1) or DL/VA ≥ 40% of predicted (a pulmonary&#xD;
             function test).&#xD;
&#xD;
          -  Karnofsky performance status &gt; 70.&#xD;
&#xD;
          -  A negative pregnancy test will be required for all women of child bearing potential.&#xD;
             Breast feeding is not permitted.&#xD;
&#xD;
          -  Patients with positive HIV serology are eligible.&#xD;
&#xD;
          -  Patients who have previously been taking atorvastatin or any other statin drug will be&#xD;
             eligible as long as there is no contraindication to switch to atorvastatin (40mg/day)&#xD;
             in the opinion of the treating physician.&#xD;
&#xD;
          -  Method of stem-cell collection from the sibling donor will be at the discretion of the&#xD;
             treating physician. Although it is anticipated that majority of sibling donors will&#xD;
             undergo Granulocyte colony-stimulating factor(G-CSF) induced stem cell mobilization;&#xD;
             however donors undergoing bone marrow harvest or stem cell mobilization with&#xD;
             experimental agents (e.g. plerixafor) will remain eligible for the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled arrhythmias or uncontrolled New York Heart Association class III-IV heart&#xD;
             failure.&#xD;
&#xD;
          -  Evidence of active bacterial, viral or fungal infection at the time of transplant&#xD;
             conditioning.&#xD;
&#xD;
          -  History of intolerance or allergic reactions with atorvastatin will not be eligible.&#xD;
&#xD;
          -  Undergoing a T-cell depleted allogeneic transplantation&#xD;
&#xD;
          -  Receiving conditioning regimens containing anti-thymocyte globulin, and/or campath&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Craig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Virginia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mehdi Hamadani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Virginia University Hospitals Mary Babb Randolph Cancer Center</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Deeg HJ. How I treat refractory acute GVHD. Blood. 2007 May 15;109(10):4119-26. Epub 2007 Jan 18. Review.</citation>
    <PMID>17234737</PMID>
  </reference>
  <reference>
    <citation>Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998 Oct 1;92(7):2303-14.</citation>
    <PMID>9746768</PMID>
  </reference>
  <reference>
    <citation>Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, Przepiorka D, Davies S, Petersen FB, Bartels P, Buell D, Fitzsimmons W, Anasetti C, Storb R, Ratanatharathorn V. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000 Sep 15;96(6):2062-8.</citation>
    <PMID>10979948</PMID>
  </reference>
  <reference>
    <citation>Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, Hochberg EP, Wu CJ, Alyea EP, Soiffer RJ. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003 Sep 1;102(5):1601-5. Epub 2003 May 1.</citation>
    <PMID>12730113</PMID>
  </reference>
  <reference>
    <citation>Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89-118. Review.</citation>
    <PMID>15822172</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 13, 2012</study_first_submitted>
  <study_first_submitted_qc>August 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2012</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Mehdi Hamadani</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Graft vs Host Disease</keyword>
  <keyword>GVHD</keyword>
  <keyword>Allogeneic hematopoietic stem cell transplantation</keyword>
  <keyword>HSCT</keyword>
  <keyword>Atorvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

